Last reviewed · How we verify

Meropenem-Vaborbactam — Competitive Intelligence Brief

Meropenem-Vaborbactam (Meropenem-Vaborbactam) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Carbapenem with beta-lactamase inhibitor. Area: Infectious Disease.

marketed Carbapenem with beta-lactamase inhibitor Penicillin-binding proteins (PBPs); serine beta-lactamases Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Meropenem-Vaborbactam (Meropenem-Vaborbactam) — Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC). Meropenem-vaborbactam is a carbapenem antibiotic combined with a beta-lactamase inhibitor that kills bacteria by inhibiting cell wall synthesis while protecting the carbapenem from enzymatic degradation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Meropenem-Vaborbactam TARGET Meropenem-Vaborbactam Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC) marketed Carbapenem with beta-lactamase inhibitor Penicillin-binding proteins (PBPs); serine beta-lactamases

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Carbapenem with beta-lactamase inhibitor class)

  1. Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Meropenem-Vaborbactam — Competitive Intelligence Brief. https://druglandscape.com/ci/meropenem-vaborbactam. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: